PUBLIC COMPANY
save$RAPPRapport Therapeutics, Inc.
$RAPP32.17-2.01%Boston, MA, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase2Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
- phase2Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
- phase2A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 17, 26SELLThird Rock Ventures V, L.P.· 10% owner−$17.18M↗
- Apr 17, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$809K↗
- Apr 14, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$358K↗
- Apr 13, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$321K↗
- Apr 10, 26SELLYeleswaram Krishnaswamy· Chief Development Officer−$17K↗
🐶 Hiring Signal
next earnings Nov 5, 2026
Where Rapport Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaCNS / Neuroscience 14
News
- Steady stream of crossover rounds stock biotech's IPO pipelineBiotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.biospace · 25d ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that